Abstract
Transplant recipients were excluded from the initial clinical trials determining safety and efficacy of the landmark COVID-19 vaccines. Further, there is increasing evidence that immunosuppressed transplant recipients have a blunted antibody response to COVID-19 vaccination. In a concerning report by Sattler et al. in this issue of the JCI, kidney transplant recipients not only lacked a humoral response following two doses of Pfizer BNT162b2, but also displayed substantial impairment of the cellular response to SARS-CoV-2 antigens. This Commentary addresses potential strategies for transplant providers to evaluate and augment vaccine immunogenicity given the likelihood that COVID-19 will remain a worldwide threat to the health of transplant recipients.
Original language | English (US) |
---|---|
Article number | e151178 |
Journal | Journal of Clinical Investigation |
Volume | 131 |
Issue number | 14 |
DOIs | |
State | Published - Jul 2021 |
ASJC Scopus subject areas
- General Medicine